IDEAS home Printed from https://ideas.repec.org/a/bla/ijhplm/v37y2022i6p3028-3038.html
   My bibliography  Save this article

Does India need a new pharmaceutical policy? Examining the implications of the drug price control order

Author

Listed:
  • Rupali Kumar
  • Mahika Milind Joshi
  • Rajat Jagdish Palod
  • Sreedhar Dharmagadda

Abstract

Objectives This article aims to analyse the impact of the pharmaceutical policy on the availability, accessibility and affordability of medicines to the Indian populace. The article delves into the shortcomings of the Drug Price Control Order 2013 and highlights its real‐world implications. Methods Published literature in the form of scientific articles on the proposed reforms that took place in the pharmaceutical policy was reviewed. The study used the memorandums, laws and government decisions published by the Department of Pharmaceuticals, Ministry of Health and Family Welfare and National Pharmaceutical Pricing Authority|National Pharmaceutical Pricing Authorities. Results The pharmaceutical policy in India underwent several changes during 2013–2020 to enhance the affordability and accessibility of drugs. The stringent policy hampered innovation due to the lack of profitability to the Multinational Companies. Moreover, it was found that the impact of the price control order on the low‐cost local generic manufacturers affected much of the country's price‐sensitive population. Conclusion The pharmaceutical policy of India needs to be amended to extend its benefit to its stakeholders. The government should shift its attention to improving the quality of drugs, increasing competition amongst manufacturers and enhancing the accessibility of medicines through state/centre sponsored initiatives.

Suggested Citation

  • Rupali Kumar & Mahika Milind Joshi & Rajat Jagdish Palod & Sreedhar Dharmagadda, 2022. "Does India need a new pharmaceutical policy? Examining the implications of the drug price control order," International Journal of Health Planning and Management, Wiley Blackwell, vol. 37(6), pages 3028-3038, November.
    • Handle: RePEc:bla:ijhplm:v:37:y:2022:i:6:p:3028-3038
    DOI: 10.1002/hpm.3554
    as

    Download full text from publisher

    File URL: https://doi.org/10.1002/hpm.3554
    Download Restriction: no
    File URL: https://libkey.io/10.1002/hpm.3554?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Sahay, Arvind & Jaikumar, Saravana, 2016. "Does Pharmaceutical Price Regulation Result in Greater Access to Essential Medicines? Study of the impact of drug price control order on sales volume of drugs in India," IIMA Working Papers WP2016-02-01, Indian Institute of Management Ahmedabad, Research and Publication Department.
    2. Ajay Bhaskarabhatla, 2018. "Challenges with Fixing the Ceiling Price Under the 2013 DPCO," India Studies in Business and Economics, in: Regulating Pharmaceutical Prices in India, chapter 0, pages 81-115, Springer.
    3. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
    4. Ajay Bhaskarabhatla, 2018. "The Proposed Design to Fix Ceiling Prices Under 2013 DPCO," India Studies in Business and Economics, in: Regulating Pharmaceutical Prices in India, chapter 0, pages 71-80, Springer.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bence Kovács & Miklós Darida & Judit Simon, 2021. "Drugs Becoming Generics—The Impact of Genericization on the Market Performance of Antihypertensive Active Pharmaceutical Ingredients," IJERPH, MDPI, vol. 18(18), pages 1-20, September.
    2. Abe C. Dunn & Lasanthi Fernando & Eli Liebman, 2023. "A Direct Measure of Medical Innovation on Health Care Spending: A Condition-Specific Approach," BEA Papers 0121, Bureau of Economic Analysis.
    3. Livio Garattini & Anna Padula, 2018. "Pharmaceutical pricing conundrum: time to get rid of it?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(8), pages 1035-1038, November.
    4. Carolina Zampirolli Dias & Brian Godman & Ludmila Peres Gargano & Pâmela Santos Azevedo & Marina Morgado Garcia & Maurílio Souza Cazarim & Laís Lessa Neiva Pantuzza & Nelio Gomes Ribeiro-Junior & Andr, 2020. "Integrative Review of Managed Entry Agreements: Chances and Limitations," PharmacoEconomics, Springer, vol. 38(11), pages 1165-1185, November.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ijhplm:v:37:y:2022:i:6:p:3028-3038. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0749-6753 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.